See every side of every news story
Published loading...Updated

Addressing the Pain Points of Making Drug-Device Combination Products – Contract Pharma

Summary by contractpharma.com
The launch of HUMIRA (adalimumab) as a single-dose prefilled syringe (PFS) in 2003 marked the start of a revolution in the delivery of vial-based biological products. Overcoming the need for complex procedures that needed to be performed by trained healthcare professionals, this first PFS cleared the way for a new range of technologies that enabled patients to self-administer their drugs more easily.1 Twenty years later, the term “Drug-Device Co…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contractpharma.com broke the news in on Friday, February 7, 2025.
Sources are mostly out of (0)